N/A N=34 Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris
Acne
Primary: Level of IL-1β — 52.5; 361.2 pg/mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=186 A Treatment for Severe Inflammatory Acne Subjects
Acne Vulgaris
Primary: Change in Number of Inflammatory Lesions — -30.1 Inflammatory lesions
Phase 2 N=22 Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
Actinic Keratosis
Primary: PGA Score — 0.53 score on a scale
Phase 2 N=257 Treatment of Moderate to Severe Facial Acne Vulgaris
Acne Vulgaris
Primary: Percentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12, Intent to Treat (ITT) Population — 14.1; 15.4; 29.5; 16.4 Percentage…
Phase 2 N=66 Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne
Inflammatory Acne
Primary: Total Inflammatory Lesion Count — 18.55; 24.51; 20.04 lesions
Phase 4 N=127 A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments
Acne
Primary: Percent Change From Baseline in Total Lesions at Week 12 — -17.1; -45.6; -13.0; 7.6 Percent change in lesions
Phase 4 N=10 A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
Acne Vulgaris
Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieved Clear (0) or Almost Clear (1) on IGA Scale at Week 16 — 78 percentage of participants — p=<0.008
N/A N=100 Knowledge Evaluation and Assessment of the Effectiveness of an Education Intervention on Acne
Acne Vulgaris
Primary: Number of Correct Responses to Questionnaire Items Immediately Before and After and Educational Lecture — 79; 79; 74; 79 participants
Phase 2 N=150 Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne
Acne Vulgaris
Primary: Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment — 16; 14.58; 11.54 Percentage of…
Phase 2 N=3 Afamelanotide in Patients Suffering With Acne Vulgaris
Acne Vulgaris
Primary: The Change in Number of Facial Inflammatory Acne-related Lesions. — 46; 23.7 Lesions
Phase 2 N=52 Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
Acne Vulgaris
Primary: Total Inflammatory Facial Lesion Count at Day 85 — 21.9; 20.3; 18.5 Lesions
Phase 4 N=23 Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients
Acne Vulgaris
Primary: Global Acne Grading System Score — 32; 30.33; 21.67; 27.5 score on a scale
Phase 4 N=22 Subantimicrobial Doxycycline in Acne
Acne Vulgaris · Pediatrics
Primary: Patient Perceptions of Their Acne Treatment — 8; 8; 7; 7 score on a scale — p=0.677
Phase 4 N=28 A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris
Acne Vulgaris
Primary: Mean Change From Baseline in Total Lesion Count — -26.9 Lesions counted
Phase 3 N=547 A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
Acne Vulgaris
Primary: Absolute Change in the Inflammatory Lesion Counts on the Face — 29.4; 29.7; 15.9; 18.2 Lesions
Phase 3 N=550 A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris
Acne Vulgaris
Primary: Absolute Change in the Inflammatory Lesion Counts on the Face — 30.1; 29.8; 15.4; 16.9 Lesions
Phase 3 N=120 An Efficiency of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel in Acne
Acne
Primary: Reduction of Undesirable Effects — 26; 38; 35; 10 participants — p=0.001
Phase 4 N=20 Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)
Acne Vulgaris · Post Inflammatory Hyperpigmentation
Primary: Percentage of Participants With Improvement in Acne IGA (Investigator Global Assessment) — 92 percentage of participants
N/A N=10 Study of Two Different 10.0% Benzoyl Peroxide Creams for Mild to Moderate Acne Vulgaris
Acne Vulgaris
Primary: Number of Inflammatory Lesions (Papules and Pustules) — 6; 3; 10; 0 Lesions
Phase 4 N=123 AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
Acne Vulgaris
Primary: Absolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity (ODS) Scores at Week 24 — -2.1; -2.1 score on a scale
Phase 2 N=18 Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel
Acne Vulgaris
Primary: Change From Baseline in Inflammatory Lesion Counts at Week 12 — 22.3; 19.0 inflammatory lesions
Phase 2 N=20 Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
Acne Vulgaris
Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants
Phase 2 N=431 A Study of a New Drug Treatment for Acne
Acne Vulgaris
Primary: Change in Total Acne Lesion Counts — -26.0; -25.2; -29.4; -33.1 Lesions
Phase 2 N=20 Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients
Acne Vulgaris
Primary: Photoactive Porphyrins Level — 33.0; 24.8; 19.7 Fluorescence intensity unit
Early Phase 1 N=15 Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation
Rosacea
Primary: Kallikrein 5 (KLK5) Protease Activity — 581.1; 816.5 RFU/uL
Phase 4 N=286 A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne
Acne Vulgaris
Primary: Percentage of Participants With at Least a One Point Decrease in the Global Acne Assessment Score (GAAS) at Week 12 — 69.7; 81.4 Percentage of participants
N/A N=10 Comparison of Two Salicylic Acid Formulations
Acne Vulgaris
Primary: Physician Global Assessment — 2.65; 2.6; 2.55; 2.45 units on a scale
N/A N=45 A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris
Acne Vulgaris
Primary: Cutaneous Tolerance Scores: Erythema — -0.07 Units on a scale
Phase 4 N=207 Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea
Papulopustular Rosacea
Primary: Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) at Week 2 (LOCF: Last Observation Carried Forward) — -10.5; -9.4…
Phase 2 N=12 Topical Treatment and Prevalence of P. Acnes
Surgical Site Infection
Primary: Number of Subjects With Positive Bacterial Growth Culture Per Treatment Arms — 10; 12; 10; 10 participants